Uzgiris V I, Graves P E, Salhanick H A
Biochemistry. 1977 Feb 22;16(4):593-600. doi: 10.1021/bi00623a006.
Absorbance changes in the spectrum of cytochrome P-450 were related to the inhibition of [26-14C]cholesterol oxidation to [14C]isocaproate and pregnenolone in mitochondria from bovine corpus luteum produced by two types of ligands. Nitrogenous inhibitors, such as aminoglutethimide, elicit an absorption maximum at about 427 nm and a minimum at about 393 nm (type II), while steroidal inhibitors, such as (20R)-20-(p-tolyl)-5-pregnene-3beta,20-diol (20-tolyl-pregnenediol), cause difference spectra with maximum at about 420 nm and minimum at about 390 nm (reverse type I). The magnitude of spectral change and the amount of inhibition of pregnenolone synthesis by aminoglutethimide are closely correlated at concentrations ranging from 5 to 750 muM and by the model steroid, 20-tolyl-pregnenediol, at concentrations from 0.5 to 25 muM. The responses are concentration dependent and linear over the range of effective concentrations. The concentrations of inhibitors for the half-maximal inhibition of pregnenolone biosynthesis are identical with the concentrations producing half-maximal spectral changes within experimental error. Displacement of substrate from cytochrome P-450 and/or stabilization of the redox potential subsequent to to the ligation of heme iron is proposed as the specific mechanism of cholesterol side chain cleavage inhibition. Finding, together, the two procedures offer a sensitive, specific, and accurate means of screening inhibitors of the cholesterol side chain cleavage system.
细胞色素P - 450光谱中的吸光度变化与两种类型配体对牛黄体线粒体中[26 - 14C]胆固醇氧化为[14C]异己酸和孕烯醇酮的抑制作用有关。含氮抑制剂,如氨鲁米特,在约427 nm处产生最大吸收,在约393 nm处产生最小吸收(II型),而甾体抑制剂,如(20R)-20-(对甲苯基)-5-孕烯-3β,20-二醇(20-甲苯基-孕烯二醇),导致差异光谱,在约420 nm处最大,在约390 nm处最小(反向I型)。在5至750 μM浓度范围内,氨鲁米特引起的光谱变化幅度与孕烯醇酮合成抑制量密切相关,在0.5至25 μM浓度范围内,模型甾体20-甲苯基-孕烯二醇也是如此。在有效浓度范围内,反应呈浓度依赖性且呈线性。在实验误差范围内,孕烯醇酮生物合成半最大抑制所需的抑制剂浓度与产生半最大光谱变化的浓度相同。提出从细胞色素P - 450上置换底物和/或在血红素铁结合后稳定氧化还原电位是胆固醇侧链裂解抑制的具体机制。总之,这两种方法提供了一种灵敏、特异且准确的筛选胆固醇侧链裂解系统抑制剂的手段。